BIA
CGTX icon

Barry Investment Advisors’s Cognition Therapeutics CGTX Stock Holding History

Barry Investment Advisors’s Portfolio CGTX Stock Details CGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$9.6K Hold
10,000
– – ﹤0.01% 102
2026
Q2 		$11.5K Hold
10,000
– – ﹤0.01% 102
2026
Q1 		$7.59K Hold
10,000
– – ﹤0.01% 99
2025
Q4 		$13.5K Hold
10,000
– – ﹤0.01% 101
2025
Q3 		$13.5K Buy
+10,000
New +$13.6K ﹤0.01% 107

Other funds holding CGTX

DC
Davenport & Co Richmond, Virginia $19.9B AUM 12.67% 1-Year Est. Return
BSB
Bangor Savings Bank Bangor, Maine $1.31B AUM 12.25% 1-Year Est. Return
VCM
Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return

Barry Investment Advisors's CGTX Position: Q3 2026 in Review

Barry Investment Advisors held its Cognition Therapeutics (CGTX) position steady in Q3 2026 at 10,000 shares worth $9.6K. The position accounts for ﹤0.01% of the portfolio, ranked #102.

Barry Investment Advisors first reported a position in CGTX in Q3 2025 and has held it in 5 quarters since. The position peaked at $13.5K in Q4 2025. 4 funds tracked by Wall St. Rank hold CGTX as of Q3 2026.

  • Barry Investment Advisors held 10,000 shares of Cognition Therapeutics worth $9.6K as of Q3 2026.
  • Barry Investment Advisors left its Cognition Therapeutics share count unchanged in Q3 2026.
  • Cognition Therapeutics made up ﹤0.01% of Barry Investment Advisors's portfolio in Q3 2026, its #102 holding.
  • Barry Investment Advisors first reported a position in Cognition Therapeutics in Q3 2025 and has held it in 5 quarters since.
  • Barry Investment Advisors's Cognition Therapeutics position peaked at $13.5K in Q4 2025.
  • 4 funds tracked by Wall St. Rank held Cognition Therapeutics as of Q3 2026.

Based on Barry Investment Advisors's 13F filing for Q3 2026, filed 14 Oct 2026.